Everolimus extends lifespan similarly to rapamycin. On Stephen Spindler’s video from EHA2012 (http://ift.tt/1Ixi39E t=10:53) you can see the life extension in mice (crossed strains). Rapamycin is probably more robust than everolimus in mice but in humans we don’t know what would be a low dose. In humans, Novartis has developped a series of clinical trials with small doses of everolimus (called “RAD001”) where it shows positive effects (http://ift.tt/1Ixi3pS)
C60 is promising but there is not much data to back it. I am in very good contacts with Fathi Moussa in France, the head of the lab who obtained the 90% life extension, and he is someone I tend to trust, but it was only found once in rats with N=6. I am also in very good contacts with Iryna Pishel’s lab in Ukraine, where they are trying to reproduce the results with more animals but in mice (all is doing well for now), and the results are expected for the beginning of 2016. SURPRISINGLY, DESPITE NUMEROUS HUMANS TRYING C60, I AM NOT AWARE OF ANYONE TRYING TO REPRODUCE THE C60 LIFE EXTENSION IN RATS. Frankly, I don’t understand why that is not happening. I am aware of smaller studies like one Where are the life extensionist researchers (?). And among those who report effects at LongeCity it is not done in a scientific, precise, coordinated way so it is difficult to say anything.
So for now C60 is promising but has weak evidence. Everolimus is c o n s i d e r a b l y more robust for human effects.
De : Walter Derzko À : ‘Edouard Debonneuil’ Cc : Walter Envoyé le : Dimanche 8 février 2015 18h26Objet : RE: [GRG] Placebo-controlled, heath-primary-endpoint, everolimus crowd testing